The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with oral S-1 for advanced gastric cancer with macroscopic peritoneal metastasis.
Hironori Yamaguchi
No relevant relationships to disclose
Hironori Ishigami
No relevant relationships to disclose
Shigenobu Emoto
No relevant relationships to disclose
Hiroharu Yamashita
No relevant relationships to disclose
Joji Kitayama
No relevant relationships to disclose